Hoechst Challenges UK's ACT

23 April 1995

In what could set an important precedent for industry, Germany's Hoechst and its UK subsidiary have issued writs against the Inland Revenue challenging the British system of advanced corporation tax levied on dividends. Hoechst says it has written to the IR, although thus far there has not been time for a reply, and has issued a High Court writ, which has yet to be served on the IR.

There are two claims. One is by the parent company, Hoechst AG, relating to payment of tax credits in respect of dividends paid by Hoechst's subsidiaries in the UK; this includes tax credits of L25.25 million ($40.2 million) - plus interest - made between 1990 and end-1994 on dividends paid by Hoechst UK Ltd. The other, a claim by Hoechst UK, relates to the cash flow disadvantages of having to pay ACT when paying dividends to its parent and receiving a credit at a later stage.

Hoechst says that in both cases the difference in treatment between UK subsidiaries with UK parent companies and UK subsidiaries with non-UK-based parents is contrary to the Freedom of Establishment provisions of the Treaty of Rome or, alternatively, in breach of the Double Taxation Convention in existence between the UK and Germany.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight